Portfolio COMPANIES

The following portfolio companies are representative of recent investments made by ZMEP.

ZMEP has made investments globally in middle to late stage medical device companies which the ZMEP management team believes have high growth potential. Listed below are representative investments.

Orthosensor

Orthosensor is an early stage medical device company based in Ft. Lauderdale, Florida, developing advanced external and implantable sensor systems for applications in the field of orthopedics. The company’s sensor platform specializes in external and implanted sensors which can detect and monitor various functions in the musculoskeletal system. These sensors enable the healthcare provider, and ultimately the patient, to activate and monitor “real-time” functions of the internal human musculoskeletal system. This early detection will decrease the patient’s morbidity after a complicated surgery, enable a quicker recovery, and minimize overall healthcare costs. The company was founded by Dr. Martin Roche, one of the most successful orthopedic surgeons in Florida, who recognized the significant potential value added in early detection and monitoring of key parameters related to orthopedic implants.

GI View

G.I. View is a company that has designed a self propelled, self navigating, miniature, disposable colonoscope intended for the screening colonoscopy market. This device will help physicians improve patient care and be more cost efficient to physicians, healthcare providers and third party payers. The current advantages of the device is that the procedure does not require sedation, it provides images of both sides of the haustral folds and can be performed by nurse practitioners under supervision.

ONI Medical Systems

ONI Medical Systems, Inc. develops and markets dedicated-purpose extremity MRI systems. ONI’s product design addresses the strict needs of facilities with limited space and budgets; clinicians seeking superior diagnostic MR technologies; and patients who require a relaxed diagnostic testing experience. ONI is the maker of the MSK Extreme with v-SPECTM, which combines superior, high-field image quality in a compact, patient-friendly unit. Unlike whole-body MRI units, the MSK Extreme enables patients to have a comfortable testing experience where just the impacted extremity is enclosed by the magnet.

MobileAccess

MobileAccess is an enterprise wireless innovator with a universal platform that is designed to allow hospitals to integrate all critical wireless systems on a common infrastructure. The Company’s Universal Wireless Network provides exceptional support for current and emerging wireless technologies.

Neural Survival Technologies, Ltd.

NST has developed the Aposense series of molecules, small molecules that attach themselves to apoptotic cells in the human body (cells which are about to die). Abnormal apoptosis (process of programmed cell death) is an indication that there is a disruptive process within the patient indicative of many disease entities. A Fluorine-18 atom has been added to the molecule to provide imaging capabilities in connection with diseases or conditions in which apoptosis is exhibited, such as cancer or stroke.

Ovalum

Ovalum is an early-stage company developing a vascular interventional guidewire for use in crossing difficult and chronic total occlusions in peripheral and coronary arteries. Currently the inability to push a guidewire through an artery with a total occlusion is the key remaining obstacle to using interventional techniques rather than surgical ones to remove a blockage in one of the coronary or peripheral arteries. Ovalum has developed a simple, steerable guidewire which does not require any external energy to work.

"MAKO" NASDAQ

MAKO Surgical

MAKO Surgical Corp. is an orthopedic medical device company developing advanced solutions for minimally invasive orthopedic surgery. The company has developed the MAKO Haptic Guidance System™ (HGS). This FDA-cleared, surgeon-interactive robotic system allows surgeons to provide an innovative orthopedic procedure called MAKOplasty™ to a large, yet significantly underserved patient population suffering from early stage degenerative joint disease of the knee. The company’s product is being used on a limited basis by select orthopedic surgeons, as the company considers modifications to enhance ease of use and improve reliability. This technology will allow orthopedic surgeons to provide significant patient benefits by reducing pain and recovery time, and may also improve patient outcomes over current methods of knee replacements.